First report of linzagolix as bridge therapy for progesterone hypersensitivity, an ultra-rare disorder
{{output}}
Purpose: We report the first use of linzagolix (Yselty®), an oral GnRH antagonist, to manage progesterone hypersensitivity, an ultra-rare disorder with fewer than 200 cases reported worldwide. ... ...
